|
| 37980367 | Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). | Br J Cancer | 2024 |
| 36351060 | Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. | Cancer Res | 2023 |
| 38072760 | Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol Oncol | 2023 |
| 37621213 | Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. | Circulation | 2023 |
| 37922930 | Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. | Lancet Oncol | 2023 |
| 37022722 | Enrollment Barriers for Molecular Targeted Trials. | JAMA Oncol | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 36948922 | Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 37316414 | Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. | Clin Genitourin Cancer | 2023 |
| 37208512 | Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. | Br J Cancer | 2023 |
| 37395777 | Low-Density Lipoprotein Cholesterol Levels in Adults With Coronary Artery Disease in the US, January 2015 to March 2020. | JAMA | 2023 |
| 37091148 | Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancer. | Front Oncol | 2023 |
| 36649492 | Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. | JCO Oncol Pract | 2023 |
| 36690547 | Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects. | Eur Urol Focus | 2023 |
| 36435709 | Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. | Urol Oncol | 2023 |
| 36528473 | Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. | Urol Oncol | 2023 |
| 36111537 | Trends in Blood Pressure Treatment Intensification in Older Adults With Hypertension in the United States, 2008 to 2018. | Hypertension | 2023 |
| 36382533 | Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer. | Prostate | 2023 |
| 34374471 | Clinical translation of hyperpolarized <sup>13</sup> C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. | Magn Reson Med | 2022 |
| 35584338 | Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. | JCO Clin Cancer Inform | 2022 |
| 35533384 | Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. | Ann Intern Med | 2022 |
| 35816286 | Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 35750560 | Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. | Urol Oncol | 2022 |
| 35859180 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. | Nature | 2022 |
| 36923283 | A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. | Cancer Res Commun | 2022 |
| 36212187 | Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. | Prostate Cancer | 2022 |
| 36109521 | Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. | Nat Commun | 2022 |
| 36041194 | Spending on Insulin by U.S. Payers and Patients From 2008 to 2017. | Diabetes Care | 2022 |
| 35998921 | Validation of clinical risk models for predicting COVID-19 severity. | Emerg Med J | 2022 |
| 35929468 | Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control. | J Am Heart Assoc | 2022 |
| 35924561 | Orthostatic Hypotension in Hypertensive Adults: Harry Goldblatt Award for Early Career Investigators 2021. | Hypertension | 2022 |
| 35983951 | DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. | Oncologist | 2022 |
| 36260524 | Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 35977225 | Association of the Medicare Value-Based Purchasing Program With Changes in Patient Care Experience at Safety-net vs Non-Safety-net Hospitals. | JAMA Health Forum | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35975978 | Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized <sup>13</sup> CÂ pyruvate metabolic imaging: A technical development study. | Magn Reson Med | 2022 |
| 35321431 | APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. | Front Oncol | 2022 |
| 34886682 | Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. | Circ Heart Fail | 2022 |
| 35311349 | Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. | J Am Heart Assoc | 2022 |
| 35176163 | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 35059998 | The Emerging Role of Next-Generation Imaging in Prostate Cancer. | Curr Oncol Rep | 2022 |
| 34932386 | Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. | JCO Oncol Pract | 2022 |
| 34758912 | Hyperpolarized 1-[<sup>13</sup>C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. | Eur Urol | 2022 |
| 32286548 | Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33571636 | Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. | Ann Oncol | 2021 |
| 33652703 | Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. | Metabolites | 2021 |
| 33736831 | Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018. | J Am Coll Cardiol | 2021 |
| 33483421 | Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. | Proc Natl Acad Sci U S A | 2021 |
| 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 33658587 | Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. | Sci Rep | 2021 |